← All trials
NCT02315690
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2015
- Primary completion
- Aug 1, 2017
- Completion date
- Feb 1, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 6000
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- University of California, San FranciscoLead sponsor
- Clinton Health Access Initiative, NigeriaCollaborator
- Government of SwazilandCollaborator
- The University of Texas, DallasCollaborator
- The University of Texas, DallasOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.